Edition:
United Kingdom

Veru Inc (VERU.OQ)

VERU.OQ on NASDAQ Stock Exchange Capital Market

2.05USD
20 Jul 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$2.05
Open
$2.06
Day's High
$2.06
Day's Low
$2.04
Volume
4,669
Avg. Vol
26,773
52-wk High
$2.99
52-wk Low
$0.90

Chart for

About

Veru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceut... (more)

Overall

Beta: 1.42
Market Cap(Mil.): $110.14
Shares Outstanding(Mil.): 53.21
Dividend: --
Yield (%): --

Financials

  VERU.OQ Industry Sector
P/E (TTM): -- 30.93 32.76
EPS (TTM): -0.19 -- --
ROI: -12.89 15.07 14.61
ROE: -16.64 16.60 16.34

BRIEF-Veru Reports Q2 Loss Per Share $0.07

* VERU INC Q2 REVENUE $2.6 MLN VS $2.4 MLN Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-U.S. FDA Grants Fee Waiver For Tamsulosin Drs New Drug Application

* FDA GRANTS FEE WAIVER FOR TAMSULOSIN DRS NEW DRUG APPLICATION

22 Mar 2018

BRIEF-Veru Says On March 5 Entered Into Credit Agreement For Synthetic Royalty Financing Transaction

* VERU SAYS ON MARCH 5, ENTERED INTO CREDIT AGREEMENT FOR SYNTHETIC ROYALTY FINANCING TRANSACTION - SEC FILING

06 Mar 2018

BRIEF-Veru Q1 Loss Per Share $0.08

* REMAIN ON TRACK TO FILE WITH FDA COMPANY'S FIRST NDA FOR TAMSULOSIN DRS IN 2018

14 Feb 2018

BRIEF-Veru to Present At 2018 Genitourinary Cancers Symposium

* VERU ANNOUNCES PRESENTATION OF DATA DEMONSTRATING EFFICACY OF VERU-111 IN A TAXANE RESISTANT HUMAN PROSTATE CANCER MODEL AT THE 2018 GENITOURINARY CANCERS SYMPOSIUM

06 Feb 2018

Earnings vs. Estimates